{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-182695","form_type":"8-K","ticker":"RMD","cik":"0000943819","company_name":"RESMED INC","filed_at":"2025-08-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.746174+00:00","generated_at":"2026-05-17T12:17:36.377851+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"ResMed elects AbbVie's Nicole Mowad-Nassar to board; director Sulpizio to retire in Nov 2025","bullets":["Nicole Mowad-Nassar elected to ResMed board effective Aug 15, 2025; she is SVP at AbbVie and President of Specialty & U.S. Therapeutics Operations.","She will serve on the Compensation and Leadership Development Committee; term expires at 2025 annual meeting on Nov 19, 2025.","Director Richard Sulpizio to retire after 20 years, not standing for reelection at Nov 19 meeting; no disagreement with company.","Sulpizio previously chaired Compensation, Audit, and Nominating & Governance committees during his tenure."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-182695","json":"https://secwatch.observer/filing/0001193125-25-182695.json","markdown":"https://secwatch.observer/filing/0001193125-25-182695.md","text":"https://secwatch.observer/filing/0001193125-25-182695.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/943819/000119312525182695/0001193125-25-182695-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/943819/000119312525182695/d72598d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T12:17:36.377851+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}